Therapeutic monoclonal antibodies for migraine

US Neurology

Volumn 11, Issue 1, 2015, Pages 64-65

  Silberstein, Stephen ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Calcitonin gene related peptide (CGRP); Migraine treatment; Monoclonal antibodies

Indexed keywords

EID: 84978321076     PISSN: 17584000     EISSN: 17584019     Source Type: Journal    
DOI: 10.17925/usn.2015.11.01.64     Document Type: Article

References (15)

1. Buss NA, Henderson SJ, McFarlane M, et al.,.. Monoclonal antibody therapeutics: history and future, Curr Opin Pharmacol, 2012;12:615-22.
2. Reichert JM,.. Therapeutic monoclonal antibodies approved or in review in the European Union or United States. Available at: http://www.antibodysociety.org/news/approved_mabs.php (accessed November 15, 2014).
3. Jefferis R,.. Isotype and glycoform selection for antibody therapeutics, Arch Biochem Biophys, 2012;526:159-66.
4. Nelson AL, Dhimolea E, Reichert JM,.. Development trends for human monoclonal antibody therapeutics, Nat Rev Drug Discov, 2010;9:767-74.
5. International Nonproprietary Names (INN) for biological and biotechnological substances, World Health Organization, 2013.
6. Carden CPA, Arkenau HT, de Bono JS,.. Optimising the development of antibodies as treatment for cancer. In: Hidalgo ME, Garrett-Mayer E, Clendeninn NJ, eds, Cancer Drug Discovery and Development, New York, NY: Springer Science+Business Media, 2011.
7. Mould DR, Sweeney KRD,.. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development, Curr Opin Drug Discov Devel, 2007;10:84-96.
8. Wang W, Wang EQ, Balthasar JP,.. Monoclonal antibody pharmacokinetics and pharmacodynamics, Clin Pharmacol Ther, 2008;84:548-58.
9. Bell IM,.. Calcitonin gene-related peptide receptor antagonists: New therapeutic agents for migraine, J Med Chem, 2014;57:7838-58.
10. Zhu D, Zhang J, Zhou L, et al.,.. A human CGRP receptor antagonist antibody, AA95, is effective in inhibiting capsaicininduced increase in dermal blood flow in cynomolgus monkeys, 54th Annual Scientific Meeting, American Headache Society, Los Angeles, CA, 2012;O22.
11. Liu H, Xu C, Shi L, et al.,.. Immunohistochemical localization of the CLR/RAMP1 receptor complex in the trigeminovascular system of the cynomolgus monkey, 53rd Annual Scientific Meeting American Headache Society, Washington DC, 2011;P2.
12. Zeller J, Poulsen KT, Sutton JE, et al.,.. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat, Br J Pharmacol, 2008;155:1093-103.
13. Dodick DW, Goadsby PJ, Spierings ELH, et al.,.. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study, Lancet Neurol, 2014;13:885-92.
14. Dodick DW, Goadsby PJ, Silberstein SD, et al.,.. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial, Lancet Neurol, 2014;13:1100-7.
15. Foltz IN, Karow M, Wasserman SM,.. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know, Circulation, 2013;127:2222-30.